Bianca Lassen-Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bianca Lassen-Schmidt has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Diane Miriam Renz
Institut für Diagnostische und Interventionelle Radiologie, Arbeitsbereich Kinderradiologie, Medizinische Hochschule Hannover, Hannover, Deutschland
3 shared publications - Alexander Pfeil
Rheumazentrum (G-BA-Regeln) sowie Sektion Rheumatologie und Osteologie, Klinik für Innere Medizin III, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena, Deutschland
2 shared publications - Felix Güttler
Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University Jena, Jena, GERMANY
2 shared publications - Gunter Wolf
Department of Internal Medicine III, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany
2 shared publications - Horst Karl Hahn
Fraunhofer MEVIS
2 shared publications - Joachim Böttcher
Department of Internal Medicine III, Center of Rheumatology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany
2 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (3)
Serial evaluation of clinical, functional, and structural pulmonary changes in 10 dogs with leptospirosis
Background: Leptospirosis is a worldwide zoonosis with multisystemic consequences, including the pulmonary hemorrhage syndrome associated with a high mortality rate in dogs. Hypothesis/Objectives: Serial assessment of clinical, functional, and structural pulmonary changes in dogs with acute leptospirosis during the first 8 days of hospitalization. Animals: Ten client-owned dogs diagnosed with leptospirosis. Methods: Prospective, descriptive case series with daily clinical examination, arterial blood gas analyses on d1-4, d6, and d8 and thoracic computed tomography (CT) with pulmonary segmentation and lung densitometry analysis on d1, d4, and d8. Results: Clinical respiratory impairment was observed in most dogs during the measurement period, including 1 dog with fatal pulmonary hemorrhage. Half of the dogs showed hypoxemia (arterial partial pressure of oxygen: median, 56.6 mmHg; range, 49.6-67.8 mmHg) with increased alveolar-arterial PO2 gradient (A-a gradient) (37.9 mmHg [21.9-405.4 mmHg]) over the study period. Alveolar ventilation was only minimally affected (arterial partial pressure of carbon dioxide 35.2 mmHg [25.9-42.1 mmHg]). Quantitative CT analyses identified increased mean lung attenuation (MLA) in all dogs initially (−612 HU [−475 to −681 HU]) with progressive improvement in most dogs (d4: −646 HU [−583 to −746 HU]; d8: −709 HU [−624 to −811 HU]). Whereas clinical score and CT changes improved progressively in most dogs, the blood gas results showed a fluctuating pattern. Conclusions and clinical importance: The clinical pulmonary manifestations of these dogs with leptospirosis were characterized by hypoxemia, increased A-a gradient, and increased lung density. The clinical course seemed to more closely parallel the structural changes observed on CT rather than the functional alterations assessed with arterial blood gas analyses.
- 4 May 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (3)
Open AccessSerial evaluation of clinical, functional, and structural pulmonary changes in 10 dogs with leptospirosis
Background: Leptospirosis is a worldwide zoonosis with multisystemic consequences, including the pulmonary hemorrhage syndrome associated with a high mortality rate in dogs. Hypothesis/Objectives: Serial assessment of clinical, functional, and structural pulmonary changes in dogs with acute leptospirosis during the first 8 days of hospitalization. Animals: Ten client-owned dogs diagnosed with leptospirosis. Methods: Prospective, descriptive case series with daily clinical examination, arterial blood gas analyses on d1-4, d6, and d8 and thoracic computed tomography (CT) with pulmonary segmentation and lung densitometry analysis on d1, d4, and d8. Results: Clinical respiratory impairment was observed in most dogs during the measurement period, including 1 dog with fatal pulmonary hemorrhage. Half of the dogs showed hypoxemia (arterial partial pressure of oxygen: median, 56.6 mmHg; range, 49.6-67.8 mmHg) with increased alveolar-arterial PO2 gradient (A-a gradient) (37.9 mmHg [21.9-405.4 mmHg]) over the study period. Alveolar ventilation was only minimally affected (arterial partial pressure of carbon dioxide 35.2 mmHg [25.9-42.1 mmHg]). Quantitative CT analyses identified increased mean lung attenuation (MLA) in all dogs initially (−612 HU [−475 to −681 HU]) with progressive improvement in most dogs (d4: −646 HU [−583 to −746 HU]; d8: −709 HU [−624 to −811 HU]). Whereas clinical score and CT changes improved progressively in most dogs, the blood gas results showed a fluctuating pattern. Conclusions and clinical importance: The clinical pulmonary manifestations of these dogs with leptospirosis were characterized by hypoxemia, increased A-a gradient, and increased lung density. The clinical course seemed to more closely parallel the structural changes observed on CT rather than the functional alterations assessed with arterial blood gas analyses.
- Open Access
- 12 August 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (9) , 1-12
The association of symptoms, pulmonary function test and computed tomography in interstitial lung disease at the onset of connective tissue disease: an observational study with artificial intelligence analysis of high-resolution computed tomography
Interstitial lung disease (ILD) is a common and serious organ manifestation in patients with connective tissue disease (CTD), but it is uncertain whether there is a difference in ILD between symptomatic and asymptomatic patients. Therefore, we conducted a study to evaluate differences in the extent of ILD based on radiological findings between symptomatic/asymptomatic patients, using an artificial intelligence (AI)-based quantification of pulmonary high-resolution computed tomography (AIpqHRCT). Within the study, 67 cross-sectional HRCT datasets and clinical data (including pulmonary function test) of consecutively patients (mean age: 57.1 ± 14.7 years, woman n = 45; 67.2%) with both, initial diagnosis of CTD, with systemic sclerosis being the most frequent (n = 21, 31.3%), and ILD (all without immunosuppressive therapy), were analysed using AIqpHRCT. 25.4% (n = 17) of the patients with ILD at initial diagnosis of CTD had no pulmonary symptoms. Regarding the baseline characteristics (age, gender, disease), there were no significant difference between the symptomatic and asymptomatic group. The pulmonary function test (PFT) revealed the following mean values (%predicted) in the symptomatic and asymptomatic group, respectively: Forced vital capacity (FVC) 69.4 ± 17.4% versus 86.1 ± 15.8% (p = 0.001), and diffusing capacity of the lung for carbon monoxide (DLCO) 49.7 ± 17.9% versus 60.0 ± 15.8% (p = 0.043). AIqpHRCT data showed a significant higher amount of high attenuated volume (HAV) (14.8 ± 11.0% versus 8.9 ± 3.9%; p = 0.021) and reticulations (5.4 ± 8.7% versus 1.4 ± 1.5%; p = 0.035) in symptomatic patients. A quarter of patients with ILD at the time of initial CTD diagnosis had no pulmonary symptoms, showing DLCO were reduced in both groups. Also, AIqpHRCT demonstrated clinically relevant ILD in asymptomatic patients. These results underline the importance of an early risk adapted screening for ILD also in asymptomatic CTD patients, as ILD is associated with increased mortality.
- 12 August 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (9) , 1-12
Open AccessThe association of symptoms, pulmonary function test and computed tomography in interstitial lung disease at the onset of connective tissue disease: an observational study with artificial intelligence analysis of high-resolution computed tomography
Interstitial lung disease (ILD) is a common and serious organ manifestation in patients with connective tissue disease (CTD), but it is uncertain whether there is a difference in ILD between symptomatic and asymptomatic patients. Therefore, we conducted a study to evaluate differences in the extent of ILD based on radiological findings between symptomatic/asymptomatic patients, using an artificial intelligence (AI)-based quantification of pulmonary high-resolution computed tomography (AIpqHRCT). Within the study, 67 cross-sectional HRCT datasets and clinical data (including pulmonary function test) of consecutively patients (mean age: 57.1 ± 14.7 years, woman n = 45; 67.2%) with both, initial diagnosis of CTD, with systemic sclerosis being the most frequent (n = 21, 31.3%), and ILD (all without immunosuppressive therapy), were analysed using AIqpHRCT. 25.4% (n = 17) of the patients with ILD at initial diagnosis of CTD had no pulmonary symptoms. Regarding the baseline characteristics (age, gender, disease), there were no significant difference between the symptomatic and asymptomatic group. The pulmonary function test (PFT) revealed the following mean values (%predicted) in the symptomatic and asymptomatic group, respectively: Forced vital capacity (FVC) 69.4 ± 17.4% versus 86.1 ± 15.8% (p = 0.001), and diffusing capacity of the lung for carbon monoxide (DLCO) 49.7 ± 17.9% versus 60.0 ± 15.8% (p = 0.043). AIqpHRCT data showed a significant higher amount of high attenuated volume (HAV) (14.8 ± 11.0% versus 8.9 ± 3.9%; p = 0.021) and reticulations (5.4 ± 8.7% versus 1.4 ± 1.5%; p = 0.035) in symptomatic patients. A quarter of patients with ILD at the time of initial CTD diagnosis had no pulmonary symptoms, showing DLCO were reduced in both groups. Also, AIqpHRCT demonstrated clinically relevant ILD in asymptomatic patients. These results underline the importance of an early risk adapted screening for ILD also in asymptomatic CTD patients, as ILD is associated with increased mortality.
- Open Access
- 9 September 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2483-2496
Artificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) for the evaluation of interstitial lung disease in patients with inflammatory rheumatic diseases
High-resolution computed tomography (HRCT) is important for diagnosing interstitial lung disease (ILD) in inflammatory rheumatic disease (IRD) patients. However, visual ILD assessment via HRCT often has high inter-reader variability. Artificial intelligence (AI)-based techniques for quantitative image analysis promise more accurate diagnostic and prognostic information. This study evaluated the reliability of artificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) in IRD-ILD patients and verified IRD-ILD quantification using AIqpHRCT in the clinical setting. Reproducibility of AIqpHRCT was verified for each typical HRCT pattern (ground-glass opacity [GGO], non-specific interstitial pneumonia [NSIP], usual interstitial pneumonia [UIP], granuloma). Additional, 50 HRCT datasets from 50 IRD-ILD patients using AIqpHRCT were analysed and correlated with clinical data and pulmonary lung function parameters. AIqpHRCT presented 100% agreement (coefficient of variation = 0.00%, intraclass correlation coefficient = 1.000) regarding the detection of the different HRCT pattern. Furthermore, AIqpHRCT data showed an increase of ILD from 10.7 ± 28.3% (median = 1.3%) in GGO to 18.9 ± 12.4% (median = 18.0%) in UIP pattern. The extent of fibrosis negatively correlated with FVC (ρ=-0.501), TLC (ρ=-0.622), and DLCO (ρ=-0.693) (p < 0.001). GGO measured by AIqpHRCT also significant negatively correlated with DLCO (ρ=-0.699), TLC (ρ=-0.580) and FVC (ρ=-0.423). For the first time, the study demonstrates that AIpqHRCT provides a highly reliable method for quantifying lung parenchymal changes in HRCT images of IRD-ILD patients. Further, the AIqpHRCT method revealed significant correlations between the extent of ILD and lung function parameters. This highlights the potential of AIpqHRCT in enhancing the accuracy of ILD diagnosis and prognosis in clinical settings, ultimately improving patient management and outcomes.
- 9 September 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2483-2496
Open AccessArtificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) for the evaluation of interstitial lung disease in patients with inflammatory rheumatic diseases
High-resolution computed tomography (HRCT) is important for diagnosing interstitial lung disease (ILD) in inflammatory rheumatic disease (IRD) patients. However, visual ILD assessment via HRCT often has high inter-reader variability. Artificial intelligence (AI)-based techniques for quantitative image analysis promise more accurate diagnostic and prognostic information. This study evaluated the reliability of artificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) in IRD-ILD patients and verified IRD-ILD quantification using AIqpHRCT in the clinical setting. Reproducibility of AIqpHRCT was verified for each typical HRCT pattern (ground-glass opacity [GGO], non-specific interstitial pneumonia [NSIP], usual interstitial pneumonia [UIP], granuloma). Additional, 50 HRCT datasets from 50 IRD-ILD patients using AIqpHRCT were analysed and correlated with clinical data and pulmonary lung function parameters. AIqpHRCT presented 100% agreement (coefficient of variation = 0.00%, intraclass correlation coefficient = 1.000) regarding the detection of the different HRCT pattern. Furthermore, AIqpHRCT data showed an increase of ILD from 10.7 ± 28.3% (median = 1.3%) in GGO to 18.9 ± 12.4% (median = 18.0%) in UIP pattern. The extent of fibrosis negatively correlated with FVC (ρ=-0.501), TLC (ρ=-0.622), and DLCO (ρ=-0.693) (p < 0.001). GGO measured by AIqpHRCT also significant negatively correlated with DLCO (ρ=-0.699), TLC (ρ=-0.580) and FVC (ρ=-0.423). For the first time, the study demonstrates that AIpqHRCT provides a highly reliable method for quantifying lung parenchymal changes in HRCT images of IRD-ILD patients. Further, the AIqpHRCT method revealed significant correlations between the extent of ILD and lung function parameters. This highlights the potential of AIpqHRCT in enhancing the accuracy of ILD diagnosis and prognosis in clinical settings, ultimately improving patient management and outcomes.
- Open Access
- 3 June 2024
- Published by Springer Nature in Datenbank-Spektrum
- Vol. 24 (2) , 117-128
Making Epidemiological and Clinical Studies FAIR Using the Example of COVID-19
FAIRification of personal health data is of utmost importance to improve health research and political as well as medical decision-making, which ultimately contributes to a better health of the general population. Despite the many advances in information technology, several obstacles such as interoperability problems remain and relevant research on the health topic of interest is likely to be missed out due to time-consuming search and access processes. A recent example is the COVID-19 pandemic, where a better understanding of the virus’ transmission dynamics as well as preventive and therapeutic options would have improved public health and medical decision-making. Consequently, the NFDI4Health Task Force COVID-19 was established to foster the FAIRification of German COVID-19 studies.This paper describes the various steps that have been taken to create low barrier workflows for scientists in finding and accessing German COVID-19 research. It provides an overview on the building blocks for FAIR health research within the Task Force COVID-19 and how this initial work was subsequently expanded by the German consortium National Research Data Infrastructure for Personal Health Data (NFDI4Health) to cover a wider range of studies and research areas in epidemiological, public health and clinical research. Lessons learned from the Task Force helped to improve the respective tasks of NFDI4Health.
- 3 June 2024
- Published by Springer Nature in Datenbank-Spektrum
- Vol. 24 (2) , 117-128
Open AccessMaking Epidemiological and Clinical Studies FAIR Using the Example of COVID-19
FAIRification of personal health data is of utmost importance to improve health research and political as well as medical decision-making, which ultimately contributes to a better health of the general population. Despite the many advances in information technology, several obstacles such as interoperability problems remain and relevant research on the health topic of interest is likely to be missed out due to time-consuming search and access processes. A recent example is the COVID-19 pandemic, where a better understanding of the virus’ transmission dynamics as well as preventive and therapeutic options would have improved public health and medical decision-making. Consequently, the NFDI4Health Task Force COVID-19 was established to foster the FAIRification of German COVID-19 studies.This paper describes the various steps that have been taken to create low barrier workflows for scientists in finding and accessing German COVID-19 research. It provides an overview on the building blocks for FAIR health research within the Task Force COVID-19 and how this initial work was subsequently expanded by the German consortium National Research Data Infrastructure for Personal Health Data (NFDI4Health) to cover a wider range of studies and research areas in epidemiological, public health and clinical research. Lessons learned from the Task Force helped to improve the respective tasks of NFDI4Health.
- Open Access
- 25 May 2024
- Published by Elsevier in European Journal of Radiology
- Vol. 176, 111534
Cooperative AI training for cardiothoracic segmentation in computed tomography: An iterative multi-center annotation approach
- 25 May 2024
- Published by Elsevier in European Journal of Radiology
- Vol. 176, 111534
Open AccessCooperative AI training for cardiothoracic segmentation in computed tomography: An iterative multi-center annotation approach
- Open Access
- 11 October 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 2553-2566
When Treatment of Pulmonary Emphysema with Endobronchial Valves Did Not Work: Evaluation of Quantitative CT Analysis and Pulmonary Function Tests Before and After Valve Explantation
Purpose: To investigate changes in quantitative CT analysis (QCT) and pulmonary function tests (PFT) in pulmonary emphysema patients who required premature removal of endobronchial valves (EBV). Patients and Methods: Our hospital’s medical records listed 274 patients with high-grade COPD (GOLD stages 3 and 4) and pulmonary emphysema who were treated with EBV to reduce lung volume. Prior to intervention, a complete evaluation was performed that included quantitative computed tomography analysis (QCT) of scans acquired at full inspiration and full expiration, pulmonary function tests (PFT), and paraclinical findings (6-minute walking distance test (6MWDT) and quality of life questionnaires). In 41 of these 274 patients, EBV treatment was unsuccessful and the valves had to be removed for various reasons. A total of 10 of these 41 patients ventured a second attempt at EBV therapy and underwent complete reevaluation. In our retrospective study, results from three time points were compared: Before EBV implantation (BL), after EBV implantation (TP2), and after EBV explantation (TP3). QCT parameters included lung volume, total emphysema score (TES, ie, the emphysema index) and the 15th percentile of lung attenuation (P15) for the whole lung and each lobe separately. Differences in these parameters between inspiration and expiration were calculated (Vol. Diff (%), TES Diff (%), P15 Diff (%)). The results of PFT and further clinical tests were taken from the patient’s records. Results: We found persistent therapy effect in the target lobe even after valve explantation together with a compensatory hyperinflation of the rest of the lung. As a result of these two divergent effects, the volume of the total lung remained rather constant. Furthermore, there was a slight deterioration of the emphysema score for the whole lung, whereas the TES of the target lobe persistently improved. Conclusion: Interestingly, we found evidence that, contrary to our expectations, unsuccessful EBV therapy can have a persistent positive effect on target lobe QCT scores.
- 11 October 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 2553-2566
Open AccessWhen Treatment of Pulmonary Emphysema with Endobronchial Valves Did Not Work: Evaluation of Quantitative CT Analysis and Pulmonary Function Tests Before and After Valve Explantation
Purpose: To investigate changes in quantitative CT analysis (QCT) and pulmonary function tests (PFT) in pulmonary emphysema patients who required premature removal of endobronchial valves (EBV). Patients and Methods: Our hospital’s medical records listed 274 patients with high-grade COPD (GOLD stages 3 and 4) and pulmonary emphysema who were treated with EBV to reduce lung volume. Prior to intervention, a complete evaluation was performed that included quantitative computed tomography analysis (QCT) of scans acquired at full inspiration and full expiration, pulmonary function tests (PFT), and paraclinical findings (6-minute walking distance test (6MWDT) and quality of life questionnaires). In 41 of these 274 patients, EBV treatment was unsuccessful and the valves had to be removed for various reasons. A total of 10 of these 41 patients ventured a second attempt at EBV therapy and underwent complete reevaluation. In our retrospective study, results from three time points were compared: Before EBV implantation (BL), after EBV implantation (TP2), and after EBV explantation (TP3). QCT parameters included lung volume, total emphysema score (TES, ie, the emphysema index) and the 15th percentile of lung attenuation (P15) for the whole lung and each lobe separately. Differences in these parameters between inspiration and expiration were calculated (Vol. Diff (%), TES Diff (%), P15 Diff (%)). The results of PFT and further clinical tests were taken from the patient’s records. Results: We found persistent therapy effect in the target lobe even after valve explantation together with a compensatory hyperinflation of the rest of the lung. As a result of these two divergent effects, the volume of the total lung remained rather constant. Furthermore, there was a slight deterioration of the emphysema score for the whole lung, whereas the TES of the target lobe persistently improved. Conclusion: Interestingly, we found evidence that, contrary to our expectations, unsuccessful EBV therapy can have a persistent positive effect on target lobe QCT scores.
- 1 January 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (1) , E18-E28
Automated Assessment of COVID-19 Reporting and Data System and Chest CT Severity Scores in Patients Suspected of Having COVID-19 Using Artificial Intelligence
Background The COVID-19 pandemic has spread across the globe with alarming speed, morbidity and mortality. Immediate triage of suspected patients with chest infections caused by COVID-19 using ches...
- 1 January 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (1) , E18-E28
Automated Assessment of COVID-19 Reporting and Data System and Chest CT Severity Scores in Patients Suspected of Having COVID-19 Using Artificial Intelligence
Background The COVID-19 pandemic has spread across the globe with alarming speed, morbidity and mortality. Immediate triage of suspected patients with chest infections caused by COVID-19 using ches...